25 Mg (14) 28 Count

25 Mg (14) 28 Count Uses, Dosage, Side Effects, Food Interaction and all others data.

25 Mg (14) 28 Count, or YKP-3089, is an antiepileptic drug developed by SK Pharmaceuticals and used to treat partial onset seizures. The exact mechanism of action has not been described in the literature, though it positively modulates GABAA and inhibits voltage gated sodium channels.

25 Mg (14) 28 Count was granted FDA approval on 21 November 2019.

The mechanism of cenobamate is unknown, however it modulates GABAA and inhibit voltage gated sodium channels. 25 Mg (14) 28 Count is given once daily and so it has a long duration of action. The therapeutic window is wide as doses of 750mg can be well tolerated. Patients should be counselled regarding the risk of DRESS syndrome, QT interval shortening, suicidal behavior, and neurological adverse effects.

25 Mg (14) 28 Count
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	25 Mg (14) 28 Count
Availability	Prescription only
Generic	Cenobamate
Cenobamate Other Names	Cenobamate, Cénobamate, Cenobamato, Cenobamatum
Related Drugs	diazepam, topiramate, levetiracetam, Keppra, Topamax, Valium
Type
Formula	C₁₀H₁₀ClN₅O₂
Weight	Average: 267.67 Monoisotopic: 267.0523023
Protein binding	Cenobamate is 60% protein bound in plasma, mainly serum albumin.
Groups	Approved, Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

25 Mg (14) 28 Count is a small molecule drug indicated to treat partial onset seizures in adults.

25 Mg (14) 28 Count is indicated for the treatment of partial onset seizures in adults.

25 Mg (14) 28 Count is also used to associated treatment for these conditions: Partial-Onset Seizures

How 25 Mg (14) 28 Count works

25 Mg (14) 28 Count inhibits voltage gated sodium channels and is a positive GABA_A modulator. However, the exact mechanism of action remains unknown. Inhibition of voltage gated sodium channels increases the threshold for generating action potentials and decreases the number of action potentials.

Toxicity

There is limited information regarding the signs, symptoms, and treatment of a cenobamate overdose. Symptomatic and supportive treatment is recommended and there is limited data on the utility of dialysis to remove cenobamate from blood.

Food Interaction

Avoid alcohol. Alcohol may increase somnolence and sedation.
Take with or without food.

25 Mg (14) 28 Count Alcohol interaction

[Moderate] GENERALLY AVOID:

Alcohol may potentiate some of the pharmacologic effects of central nervous system (CNS)-active agents.

Use in combination may result in additive CNS depression and/or impairment of judgment, thinking, and psychomotor skills.

Patients receiving CNS-active agents should be advised to avoid or limit consumption of alcohol.

Ambulatory patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.

25 Mg (14) 28 Count Drug Interaction

Moderate: perampanel, lamotrigine, atorvastatin, dextromethorphan / guaifenesin, esomeprazole, clobazam, topiramate, ubrogepantUnknown: fremanezumab, naproxen, albuterol / ipratropium, fluticasone, metoprolol, albuterol, acetaminophen, albuterol, lacosamide, cyanocobalamin

Volume of Distribution

The apparent volume of distribution of cenobamate is 40-50L.

Elimination Route

25 Mg (14) 28 Count is 88% orally bioavailable with a T_max of 1-4 hours. A high fat meal does not significantly impact the pharmacokinetics of cenobamate.